Posts by Immunexpress

International Sepsis Forum 2017

International Sepsis Forum 2017 11-13 September, 2017 Paris, France Dr Leo McHugh presented an algorithmic method for interpreting the performance of high accuracy diagnostics when judged against clinical diagnoses known to contain uncertainty. This is the first public release of this method and associated open-course software for the diagnostics community. The method and software has…

Read More

Biocartis & Immunexpress Sign Partnership for a Sepsis Host Immune Response Test on the Idylla™ platform

Immunexpress.com

Mechelen (Belgium)/Seattle (United States), 24 January 2018 – Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART) and Immunexpress Pty Ltd (‘Immunexpress’), a host response molecular diagnostic company, committed to improving clinical and economic outcomes for suspected sepsis patients, today announce that they have entered into a partnership agreement aimed at the…

Read More

Immunexpress Appoints Rolland Carlson, Ph.D., as Chief Executive Officer

Immunexpress.com

Industry veteran brings a successful track record fundraising and launching commercial products Appointment strengthens the leadership team and positions the company for its targeted commercial launch   SEATTLE, April 10, 2018 – Immunexpress, Inc. today announced the appointment of Rolland D. Carlson, Ph.D., as chief executive officer, effective April 9, 2018. Dr. Carlson most recently…

Read More

SeptiCyte™ LAB Differentiates Sepsis from SIRS in the ICU

Immunexpress.com

Design and results of clinical trials that led to FDA clearance of SeptiCyte™ LAB published in the American Journal of Respiratory and Clinical Care Medicine SEATTLE, May 9, 2018 /PRNewswire/ — Immunexpress, Inc. today announced the publication in the American Journal of Respiratory and Clinical Care Medicine of the design and results of clinical trials validating SeptiCyte™ LAB in the…

Read More

Immunexpress and Academic Medical Center to Collaborate on Development of Sepsis-Related Biomarker Panels

Immunexpress.com

SEATTLE, April 19, 2016 — Immunexpress Inc. today announced an exclusive collaboration with the Academic Medical Center (AMC) at the University of Amsterdam to characterize and clinically evaluate sepsis and sepsis-related biomarker signatures of the host response. This four-year collaboration with AMC’s Prof. Dr. Tom van der Poll and his team will leverage the informatics expertise…

Read More

Immunexpress Presents on the Need for an Objective Diagnostic Tool for Systemic Inflammation at the International Symposium on Intensive Care and Emergency Medicine

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced the presentation of data from the VENUS trial by Dr. Bert Lopansri of Intermountain Medical Center at the 36th International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium. The presentation describes the diagnostic variability observed between physicians…

Read More

Immunexpress Announces Presentation at the 36th International Symposium on Intensive Care and Emergency Medicine on the Need for an Objective Diagnostic Tool for Systemic Inflammation

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from the VENUS trial showing the discordance between clinical impressions of patients with systemic inflammation will be presented at the upcoming 36th International Symposium on Intensive Care and Emergency Medicine on Mar. 15 in Brussels, Belgium. Poster…

Read More

Immunexpress Secures U.S. Patent for Immune Biomarkers for Herpes Virus Infection

Immunexpress.com

Immunexpress Secures U.S. Patent for Immune Biomarkers for Herpes Virus Infection SEATTLE, United States (November 21, 2012) – Today, Immunexpress Group announced the granting in the United States (U.S.) of one of its core biomarker patents, “microarray-mediated diagnosis of herpes virus infection by monitoring host’s differential gene expression upon treatment.” The patent covers host response…

Read More

Immunexpress Announces New Collaboration with MARS Consortium to Improve Care of Sepsis Patients

Immunexpress.com

Immunexpress Announces New Collaboration with MARS Consortium to Improve Care of Sepsis Patients The MARS Consortium is one of the largest collaborations of academic and industry partners dedicated solely to improving sepsis outcomes SEATTLE, United States / EINDHOVEN, The Netherlands (April 10, 2013) –Today, the Immunexpress Group announced its collaboration with the Molecular Diagnosis and…

Read More

Immunexpress Secures New EU Patent for Immune Biomarkers for Herpes Virus Infection

Immunexpress.com

Immunexpress Secures New EU Patent for Immune Biomarkers for Herpes Virus Infection April 1, 2013 – Today, Immunexpress Group announced the granting of one of its core biomarker patents, “microarray-mediated diagnosis of herpes virus infection by monitoring host’s differential gene expression upon treatment” in the European Union (EU). This patent compliments the U.S. herpes virus…

Read More